For those of you worried about the "Melenoma Strategy" Language. This is the reply. No worries.
Hi Jack,
Thank you for reaching out. In regards to your inquiry, we have continually outlined 3 potential paths forward for our melanoma combination study. Therefore, outlining our study strategy further would be an important milestone for the company. We plan to initiate a combination study in 2014.
Thank you for your continued interest and support. Have a great rest of the week!
Best Regards, Corporate Communications Team 855.662.6732 | investors@oncosec.com